Martingale Asset Management L P Prothena Corp Public LTD CO Transaction History

Martingale Asset Management L P

  • $4.27 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$47.3 - $70.6 $51,888 - $77,448
1,097 Added 9.69%
12,415 $599,000
Q2 2023

Aug 11, 2023
BUY
$48.26 - $78.59 $546,206 - $889,481
11,318 New
11,318 $772,000
Q4 2020

Feb 10, 2021
SELL
$10.12 - $13.94 $451,706 - $622,211
-44,635 Closed
0 $0
Q3 2020

Nov 12, 2020
SELL
$9.93 - $13.47 $602,751 - $817,629
-60,700 Reduced 57.63%
44,635 $445,000
Q2 2020

Aug 10, 2020
BUY
$9.56 - $12.51 $1.01 Million - $1.32 Million
105,335 New
105,335 $1.1 Million

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $714M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Martingale Asset Management L P Portfolio

Follow Martingale Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email